TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04822831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 45 Degree Semi-recumbent Position With Upper Limb Exercise Training
Description: The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training
Description: The control group was with usual treatment.
Study: NCT04439682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
Study: NCT00825916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100 Drug Product
Description: Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100 Drug Product
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT01653067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Temsirolimus, DHAP, intravenous
Description: Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
Study: NCT02013518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioural Therapy
Description: 11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
Study: NCT01742611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study: NCT01884467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Comparison of Gentamicin versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01414140

Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Women inserted Mirena for intrauterine contraception.
Study: NCT04866498

Intervention type: DRUG
Intervention: Infusion Intravenous
Study: NCT02212210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01207297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
Study: NCT03404141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent craft
Description: Midwife-guided classes for pregnant women about pregnancy and childbirth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
Study: NCT03418831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene Hydrochloride
Description: 60 mg per capsule (1 tablet daily) for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 12 weeks
Study: NCT04141969

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RLP
Description: RLP nutraceutical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert brown powder
Study: NCT01657513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subjects will receive either infliximab, adalimumab or etanercept
Description: The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines
Study: NCT04485182

Intervention type: OTHER
Intervention: Underwater jet massage (Tangentor)
Description: Underwater jet massage (Tangentor) would be performed in a tub developed for this purpose, where the water temperature: 33-35 ° C. The treatments lasting from 15 atm and 15 cm for 15 minutes.~They take a minimum of 10 treatments for approx. under 2 weeks.
Study: NCT03203395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and counselling
Description: Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
Study: NCT03742921

Intervention type: DRUG
Intervention: Istodax
Description: Istodax
Study: NCT03501641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: image-based virtual reality learning
Description: The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video-based learning
Description: voice of the staffs and standard patients.
Study: NCT04117555

Intervention type: DIAGNOSTIC_TEST
Intervention: Pupil response to light stimuli
Description: Objective and accurate measurement of pupillary responses to light stimuli

Intervention type: DIAGNOSTIC_TEST
Intervention: Pupil response to light stimuli
Description: Objective and accurate measurement of pupillary responses to light stimuli
Study: NCT00904449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: 10mg, 20mg, and 40mg PO
Study: NCT04402138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
Study: NCT04701827

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AWARE intervention
Description: Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).
Study: NCT05684822

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
Study: NCT02302599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Description: Infusion treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Controlled suspension liquid
Description: Infusion treatment
Study: NCT02123901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Meditation
Description: Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Meditation
Description: Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Sedentary life style.
Study: NCT02552043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii exercise program
Description: The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
Study: NCT02792686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Single Administration
Study: NCT03377608

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit

Intervention type: DRUG
Intervention: Depo-Provera
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
Study: NCT01294553

Intervention type: DRUG
Intervention: Administration of rosiglitazone/metformin
Description: Subjects who are administered rosiglitazone/metformin at least once
Study: NCT03077334

Intervention type: DEVICE
Intervention: PET-CT
Description: PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.

Intervention type: DEVICE
Intervention: PET-CT
Description: PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
Study: NCT01217229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
Study: NCT01481844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole
Description: use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline
Description: this combination is standard of care as H pylori second line treatment
Study: NCT02665390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous cryoablation
Description: Percutaneous cryoablation
Study: NCT01151189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A/AERAS-485
Description: Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
Study: NCT03729739

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: QFR-based diagnostic strategy
Description: Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR-based diagnostic strategy
Description: Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
Study: NCT02080806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Insufflation Exsufflation
Description: Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
Study: NCT04529902

Intervention type: DRUG
Intervention: Tumor Necrosis Factor Inhibitors
Description: TNFi claim is used as the reference group.

Intervention type: DRUG
Intervention: Abatacept
Description: Abatacept claim is used as the exposure group.
Study: NCT00966277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: 5000 units subcutaneous, by injection under the skin, daily for 16 weeks
Study: NCT05748691

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical implementation of hs-cTnT
Description: To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
Study: NCT04503343

Intervention type: OTHER
Group type: OTHER
Intervention: non-drug intervention
Description: mindfulness training, relaxation training, or electrical cerebellar stimulation
Study: NCT01975974

Intervention type: DEVICE
Intervention: Ultrasound
Description: Using ultrasound as a guide for peripheral venous cannulation in obese patients
Study: NCT02875977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: A 4-minute educational video describing PFPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational handout
Description: A 2-page educational handout describing PFPT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational handout
Description: A 2-page educational handout describing PFPT
Study: NCT02754817

Intervention type: DRUG
Intervention: insulin degludec/liraglutide
Description: This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
Study: NCT00841880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril + Felodipine
Description: Ramipril 5mg + Felodipine 5mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 10 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 5mg once a day
Study: NCT04606043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sandblasting
Description: Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acid Etching
Description: Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
Study: NCT06084156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653
Description: Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
Study: NCT01442818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid PCA
Description: PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid IV Scheduled
Description: Nurse administered IV Dilaudid 0.5mg every 2 hours.
Study: NCT04646915

Intervention type: OTHER
Intervention: Day surgery
Description: Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
Study: NCT01517646

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT01718353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL (XRP6976)
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL (XRP6258)
Description: Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT04299438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Hydrochloride
Description: 2mg/mL vials

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline in vials matching the vials of the active drug
Study: NCT02881905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ball attachment
Description: it is attachment part that connects the overdenture to the implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cm loc attachment
Description: It is a new attachment made of peek material
Study: NCT02262091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food fibers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (incl. criterion)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza vaccine (incl. criterion)
Study: NCT01651442

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Insomnia Therapy
Description: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Insomnia Therapy
Description: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 5mg or 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 5mg or 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50mg to 150mg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
Study: NCT02364843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid: Threonine
Description: Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
Study: NCT01696838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.